A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran (Q43975358)
Jump to navigation
Jump to search
scientific article published in February 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran |
scientific article published in February 2002 |
Statements
1 reference
A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas tran (English)
1 reference
Rita R Alloway
1 reference
Robert J Stratta
1 reference
Ernest Hodge
1 reference
Agnes Lo
1 reference
Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group
1 reference
1 February 2002
1 reference
1 reference
16
1 reference
1
1 reference
60-68
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference